Exciting developments from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) offer new hope in the fight against pancreatic cancer.
Researchers have found that a substance called polyinosine–polycytidylic acid (pIC) could be a key player in stopping this aggressive cancer.
The study, shared in the Journal for ImmunoTherapy of Cancer, shows that pIC, when modified to enter cancer cells effectively, can stop the growth of tumors and even kill cancer cells in animal models.
This is especially important for pancreatic cancer, known as pancreatic ductal adenocarcinoma (PDAC), which is notoriously tough to treat and has low survival rates.
One of the big wins of this study is that pIC seems to be safe for normal cells while targeting the cancerous ones. When researchers combined pIC with a common cancer drug called gemcitabine, the mix worked even better.
This suggests that doctors might be able to use this new method alongside traditional treatments for even greater effects.
Extending Life in Mice Models
In mice with a healthy immune system, this new treatment approach greatly extended life. This outcome is a big deal because previous attempts with pIC alone didn’t really help fight cancer.
But with this new method of delivery, researchers are seeing results that haven’t been observed before in pancreatic cancer.
How Does pIC Work?
The secret to pIC’s success lies in its ability to wake up the body’s immune system to fight the cancer. It changes certain cells in the tumors from helping the cancer to attacking it. It’s like flipping a switch inside the body to go from growing cancer to destroying it.
Since we already know a lot about the safety of gemcitabine and pIC, researchers are hopeful about moving this treatment from animal studies to human trials.
The results in mice are so promising that they think it could make a big difference for people suffering from pancreatic cancer.
A Potential Cancer Vaccine?
An exciting side discovery was that giving pIC to mice before they developed cancer slowed down tumor growth later on.
It’s as if pIC acted like a vaccine, giving the mice some protection against cancer. This finding could open doors to new research on preventing cancer before it even starts.
The success of this treatment in mice suggests it could work for various types of cancer, not just pancreatic. There’s even early evidence from human studies that this method is safe and could be an effective treatment option.
In conclusion, this breakthrough could be a game-changer for patients with pancreatic cancer, offering a glimpse of hope for a disease that desperately needs better treatment options.
With further research and clinical trials, this new approach could soon provide a much-needed light at the end of the tunnel for those battling PDAC.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more information about cancer, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
The research findings can be found in the Journal for ImmunoTherapy of Cancer.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
